Promega OncoMate MSI

Promega Corporation has launched the OncoMate MSI Dx Analysis System in the US. The in vitro diagnostic was cleared by the US Food and Drug Administration last month as an IVD medical device and gives oncologists and pathologists a new option to screen for Lynch syndrome in patients with colorectal cancer by determining microsatellite instability (MSI) status in their tumors.

Promega said it's underlying MSI technology has been in use for more than 15 years and is supported by over 140 peer-reviewed publications.